Pfenex reports positive Phase Ia Px563L anthrax vaccine study results

US-based, clinical-stage biotechnology company Pfenex has reported a positive outcome from its Phase Ia Px563L anthrax vaccine study.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news

Related Links:

Abstract Monoclonal antibodies (mAbs) as alternatives or more often as complementary to the conventional antimicrobials are being developed for the management of infectious conditions for the past two decades. These pharmacotherapeutic strategies are inevitable as the burden of antimicrobial resistance is far-reaching in recent times. MAbs are part of the targeted pharmacotherapy armamentarium with high degree of specificity - hence, exert comparatively superior efficacy and tolerability than the conventional polyclonal antisera. So far, only five mAbs have been approved for the management of infectious states - s...
Source: Infectious Disorders Drug Targets - Category: Infectious Diseases Authors: Tags: Infect Disord Drug Targets Source Type: research
ConclusionThis gastrointestinal anthrax outbreak occurred due to eating beef from butchery X. We recommended health education, safe disposal of the carcasses of livestock or game animals, and anthrax vaccination for livestock.
Source: PLoS Neglected Tropical Diseases - Category: Tropical Medicine Authors: Source Type: research
Anthrax, whether resulting from natural or bioterrorist-associated exposure, is a constant threat to human health. Bacillus anthracis is the causative agent of anthrax. It is surrounded by a polypeptide capsule of poly-gamma-D-glutamic acid (gamma-D-PGA), which is essential for virulence, is poorly immunogenic and has anti-phagocytic properties. Antibodies to the capsule have been shown to enhance phagocytosis and killing of encapsulated bacilli. The lethality of anthrax is primarily the result of the effects of anthrax toxin, which has 3 components: a receptor-binding protein known as " protective antigen " (PA)...
Source: NIH OTT Licensing Opportunities - Category: Research Authors: Source Type: research
In conclusion, (+)-FUC-TMC-NP is promising anthrax vaccine adjuvant as an alternative to CpG.
Source: Carbohydrate Polymers - Category: Biomedical Science Source Type: research
(Natural News) As the totally discredited mainstream media continues to pretend that the coronavirus pandemic isn’t real, the truth is starting to emerge from establishment scientists who are warning the world that this outbreak cannot be contained. One of those individuals is Nancy Messonnier. She works for the CDC and previously served as an “Epidemic...
Source: NaturalNews.com - Category: Consumer Health News Source Type: news
Abstract A next-generation anthrax vaccine candidate, AV7909, is being developed for post-exposure prophylaxis (PEP) of inhalational anthrax in combination with the recommended course of antimicrobial therapy. Clinical efficacy studies of anthrax countermeasures in humans are not ethical or feasible, therefore, licensure of AV7909 for PEP is being pursued under the US Food and Drug Administration (FDA) Animal Rule, which requires that evidence of effectiveness be demonstrated in an animal model of anthrax, where results of studies in such a model can establish reasonable likelihood of AV7909 to produce clinical be...
Source: Vaccine - Category: Allergy & Immunology Authors: Tags: Vaccine Source Type: research
AbstractA 2016 outbreak of anthrax on the Yamal Peninsula in Siberia that led to the culling of more than two hundred thousand reindeer and killed one human, resulted in significant media interests and in the reporting was often linked to thawing permafrost and ultimately climate change. Here, we review the historic context of anthrax outbreaks in the circumpolar North and explore alternative explanations for the anthrax outbreak in Western Siberia. Further, we propose a convergence model where multiple factors likely contributed to the outbreak of anthrax, including an expanded population and discontinued vaccination.
Source: EcoHealth - Category: Environmental Health Source Type: research
[263Chat] The government has availed vaccines for the treatment of cattle from anthrax hit areas amid reports that 33 people have been diagnosed and hospitalized of the deadly disease in the past weeks.
Source: AllAfrica News: Health and Medicine - Category: African Health Source Type: news
Publication date: Available online 9 January 2020Source: The Brazilian Journal of Infectious DiseasesAuthor(s): Yuanyuan Liu, Yongqin Li, Qiaoxia Wang, Jianjun Fu, Fanpu JiAbstractChina’s compulsory annual livestock anthrax vaccination policy has remarkably reduced but not completely eradicated human anthrax infections. Herein we describe a sporadic human cutaneous anthrax outbreak involving two cases in 2018 in Shaanxi Province, both involving herdsman who dealt with unvaccinated and potentially sick cattle. Both patients showed Bacillus anthracis-positive blister smear and blood culture. Treatment with penicillin w...
Source: The Brazilian Journal of Infectious Diseases - Category: Infectious Diseases Source Type: research
Abstract China's compulsory annual livestock anthrax vaccination policy has remarkably reduced but not completely eradicated human anthrax infections. Herein we describe a sporadic human cutaneous anthrax outbreak involving two cases in 2018 in Shaanxi Province, both involving herdsman who dealt with unvaccinated and potentially sick cattle. Both patients showed Bacillus anthracis-positive blister smear and blood culture. Treatment with penicillin was followed by uneventful recovery for both. The prompt performance of the prophylactic measures successfully interrupted the further transmission of this sporadic huma...
Source: Braz J Infect Dis - Category: Infectious Diseases Authors: Tags: Braz J Infect Dis Source Type: research
More News: Anthrax | Anthrax Vaccine | Biotechnology | Pharmaceuticals | Study | Vaccines